Answers are grounded in this paper and cite their sources.
Bloodstream infections (BSIs) are a leading cause of morbidity and mortality in pediatric oncology-hematology patients. The local epidemiological landscape varies across centers, requiring continuous institutional surveillance. BSI episodes at a tertiary pediatric oncology-hematology center (Bari, Italy) were retrospectively reviewed over 10 years (2014 to 2024), analyzing microbiological spectrum, antimicrobial susceptibility, and the impact of 2 prophylactic policies: amoxicillin-clavulanate prophylaxis (2014 to 2019) versus its discontinuation (2019 to 2024). Among 568 newly diagnosed patients, 208 BSIs were documented in 144 (25.4%), with 93.8% monomicrobial. Gram-positive organisms predominated (61.6%), with coagulase-negative staphylococci as the most frequent isolates. Escherichia coli was the leading Gram-negative pathogen (9.5%). Eight fungal BSIs occurred exclusively in hematologic malignancies, half caused by Candida parapsilosis ; 2 were polymicrobial. Peak C-reactive protein independently predicted Gram-negative BSI in multivariable analysis (OR: 1.005; 95% CI: 1.001-1.010; P <0.05), with limited discriminatory performance (AUC: 0.62). Blood culture positivity was significantly higher during prophylaxis (5.75% vs. 3.65%; P <0.001). Multidrug-resistant organisms remained rare (3.8%), with no methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci detected. BSI-related mortality was 1.4%, confined to Gram-negative and fungal episodes. Prophylaxis discontinuation was associated with lower positivity rates. An empirical escalation strategy ensured adequate coverage while minimizing antibiotic exposure, supporting its use in this setting.
No takes yet. Share an insight, caveat, or question.
Leonardis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: